Irwin Acquisition and Early Scaling
Acquired Irwin Naturals on August 8, 2025; Irwin Q4 revenue $12.6M (89% wholesale), delivered ~6% organic growth in Q4 vs. 2024 when normalized for lost Costco/Rite Aid/CBD; Amazon ramp: Oct $60k, Nov $300k, Dec ~ $500k; online monthly run-rate grew from ~$0.5M at end of Q4 to ~$0.8M in Q1 2026 (implying $9M–$10M annualized); subscribers increased from ~500 to over 3,600.
Strong Reported Q4 Revenue Lift
Total company revenue in Q4 2025 was $25.9M, up 73% year-over-year, primarily driven by the Irwin acquisition.
Wholesale Revenue Expansion
Wholesale revenue in Q4 was $15.5M (60% of revenue), a 213% increase versus Q4 2024, reflecting acquired Irwin wholesale sales and cross-sell opportunities.
Improving Profitability Metrics (Adjusted)
Contribution (gross profit less advertising/marketing) increased 47% in Q4 2025; Adjusted EBITDA was $3.5M, up 14% year-over-year.
Debt Reduction Progress
Paid down approximately $1.9M of term loan in Q4 reducing total debt to $44.7M; further reduced revolver by $1.4M in Q1 and made an additional ~$1.5M term loan payment, noting management is ahead of schedule on deleveraging.
Healthy Performance in Non-MRC Legacy Brands
Legacy FitLife (ex-MRC and MusclePharm) delivered ~6% organic revenue growth in 2025; legacy online revenue grew ~16% for the year; excluding MRC and MusclePharm, other legacy brands delivered 4% organic growth in Q4 with higher revenue, gross margin and contribution metrics.
Operational Initiatives Launched
Management hired a new VP of Operations for Irwin and a new CMO; initiatives include shifting Irwin products to 3-year shelf life, new product development (3 Irwin SKUs in production targeting Q3 launch), off-Amazon demand generation, and cross-selling efforts into wholesale.
Early Wholesale Cross-Sell Wins
Leverage of Irwin's sales team yielded initial placement wins, including placement of 6 MusclePharm SKUs in a regional grocery chain, indicating potential channel expansion over time.